dc.contributor.author | Middleton, Mark R | |
dc.contributor.author | Dalle, Stephane | |
dc.contributor.author | Claveau, Joel | |
dc.contributor.author | Mut, Pilar | |
dc.contributor.author | Hallmeyer, Sigrun | |
dc.contributor.author | Plantin, Patrice | |
dc.contributor.author | Highley, Martin | |
dc.contributor.author | Kotapati, Srividya | |
dc.contributor.author | Le, Trong Kim | |
dc.contributor.author | Brokaw, Jane | |
dc.contributor.author | Abernethy, Amy P | |
dc.date.accessioned | 2024-07-09T09:14:04Z | |
dc.date.available | 2024-07-09T09:14:04Z | |
dc.date.issued | 2016-07 | |
dc.identifier.citation | Middleton MR, Dalle S, Claveau J, Mut Sanchís P, Hallmeyer S, Plantin P, et al. Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study. Cancer Med. 2016 Jul;5(7):1436-43. Epub 2016 Apr 26. | en |
dc.identifier.issn | 2045-7634 | |
dc.identifier.other | http://hdl.handle.net/20.500.13003/10282 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/20271 | |
dc.description.abstract | The therapeutic landscape for advanced melanoma has recently been transformed by several novel agents (immune checkpoint inhibitors and molecular-targeted agents). The prospective, multi-site, observational study IMAGE (ipilimumab: management of advanced melanoma in real practice) included a retrospective cohort to describe real-world treatment prior to approval of the immune checkpoint inhibitor ipilimumab. This retrospective cohort of patients, who started second-line/subsequent treatment (index therapy) for advanced melanoma within 3 years before ipilimumab approval, was selected randomly by chart review. Collected data included treatment history, patient outcomes, and healthcare resource utilization. All patients had >= 1 year of follow-up data. This analysis included 177 patients from Europe (69%) and North America (31%). The most common index therapies (used alone or in combination) were fotemustine (23%), dacarbazine (21%), temozolomide (14%), and platinum-based chemotherapy (14%). Most patients (89%) discontinued index treatment during the study period; the most common reason was disease progression (59%). Among patients with tumor assessment (153/177; 86%), 2% had complete response, 5% had partial response, and 12% had stable disease on last tumor assessment. At 1-year study follow-up, median progression-free survival was 2.6 months (95% confidence interval [CI], 2.1-2.9) and median overall survival was 8.8 months (95% CI, 6.5-9.7). During follow-up, 95% of the patients had healthcare visits for advanced melanoma, 74% of whom were hospitalized or admitted to a hospice facility. These results provide insights into patient care with advanced melanoma in the era before ipilimumab and may serve as a benchmark for new agents in future real-world studies. | en |
dc.description.sponsorship | This study was funded by Bristol-Myers Squibb. | es_ES |
dc.language.iso | eng | en |
dc.publisher | Wiley | en |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Advanced melanoma | |
dc.subject | Ipilimumab | |
dc.subject | Observational study | |
dc.subject | Real-world treatment practice | |
dc.subject | Retrospective | |
dc.subject.mesh | Aged, 80 and over | * |
dc.subject.mesh | Aged | * |
dc.subject.mesh | Retreatment | * |
dc.subject.mesh | Young Adult | * |
dc.subject.mesh | Adult | * |
dc.subject.mesh | Humans | * |
dc.subject.mesh | Adolescent | * |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols | * |
dc.subject.mesh | Antineoplastic Agents | * |
dc.subject.mesh | Melanoma | * |
dc.subject.mesh | Middle Aged | * |
dc.subject.mesh | Neoplasm Staging | * |
dc.subject.mesh | Male | * |
dc.subject.mesh | Molecular Targeted Therapy | * |
dc.subject.mesh | Neoplasm Metastasis | * |
dc.subject.mesh | Female | * |
dc.subject.mesh | Ipilimumab | * |
dc.subject.mesh | Treatment Outcome | * |
dc.subject.mesh | Survival Analysis | * |
dc.subject.mesh | Comorbidity | * |
dc.subject.mesh | Retrospective Studies | * |
dc.title | Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study | en |
dc.type | research article | en |
dc.rights.license | Attribution 4.0 International | * |
dc.identifier.pubmedID | 27118102 | es_ES |
dc.format.volume | 5 | es_ES |
dc.format.number | 7 | es_ES |
dc.format.page | 1436-1443 | es_ES |
dc.identifier.doi | 10.1002/cam4.717 | |
dc.relation.publisherversion | https://dx.doi.org/10.1002/cam4.717 | en |
dc.identifier.journal | Cancer Medicine | es_ES |
dc.rights.accessRights | open access | en |
dc.subject.decs | Resultado del Tratamiento | * |
dc.subject.decs | Comorbilidad | * |
dc.subject.decs | Ipilimumab | * |
dc.subject.decs | Análisis de Supervivencia | * |
dc.subject.decs | Femenino | * |
dc.subject.decs | Estadificación de Neoplasias | * |
dc.subject.decs | Metástasis de la Neoplasia | * |
dc.subject.decs | Adolescente | * |
dc.subject.decs | Masculino | * |
dc.subject.decs | Antineoplásicos | * |
dc.subject.decs | Humanos | * |
dc.subject.decs | Melanoma | * |
dc.subject.decs | Persona de Mediana Edad | * |
dc.subject.decs | Adulto Joven | * |
dc.subject.decs | Protocolos de Quimioterapia Combinada Antineoplásica | * |
dc.subject.decs | Anciano | * |
dc.subject.decs | Anciano de 80 o más Años | * |
dc.subject.decs | Terapia Molecular Dirigida | * |
dc.subject.decs | Estudios Retrospectivos | * |
dc.subject.decs | Adulto | * |
dc.subject.decs | Retratamiento | * |
dc.identifier.scopus | 2-s2.0-84991524888 | |
dc.identifier.wos | 380048900009 | |
dc.identifier.pui | L611255066 | |